| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8827406 | Transplantation Proceedings | 2018 | 4 Pages |
Abstract
Use of an anti-TNF-α agent in a liver transplant patient with inflammatory bowel disease may be an effective option, with an acceptable risk-benefit ratio. Further studies are required to confirm their use in this context.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
R.V. Olmedo-MartÃn, V. Amo-Trillo, R. González-Grande, E. Tenorio-González, O. Sánchez-GarcÃa, J. de la Cruz-Lombardo, J.M. Rodrigo-López, M. Jiménez-Pérez,